ELTX logo

ELICIO THERAPEUTICS INC

ELTXNASDAQ
๐Ÿ† #4264 by market capEarnings Mar 10 ยท PostUS Equity
$1.45โ€”
Last available close ยท quote unavailable
๐Ÿ””
Track ELTX
Get earnings, price moves & breaking news on Telegram
Track
24hโ€”
7dโ–ผ 3.0%
14dโ–ผ 4.9%
30dโ–ผ 24.3%
ytdโ–ผ 81.8%
1yโ–ผ 82.8%
๐ŸฆMarket Cap
$41M
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
-91.9%
Declining
๐Ÿ“ŠGross Margin
98.5%
High
๐Ÿ’ตFCF Margin
โ€”
โš–๏ธP/S Ratio
1.4x
Cheap
Otter Score
โ€”
Insufficient data

Trading Snapshot

Day Range
โ€”
52-Week Range
$1.25 โ€“ $16.00
Volume (shares)
โ€”
Avg Volume (shares)
โ€”
Shares Outstanding
27.1M
Next Earnings
2027-03-10

Fundamentals Snapshot

Annual Revenue
โ€”
Last Q Revenue
โ€”
P/E Ratio
โ€”
P/S Ratio
1.4x
EPS (TTM)
$-2.18
Dividend Yield
โ€”
ELTX logo

ELICIO THERAPEUTICS INC

ELTX
Financial Trends

Financial history unavailable.

StockOtter ยท stockotter.space

About ELICIO THERAPEUTICS INC

Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Insufficient data
โ€”/100

Analyst Ratings

โ“˜
Consensus
Buy
10 analysts
Strong Buy3
Buy5
Hold2
Sell0
Strong Sell0
Ratings as of Nov 2026

Latest News & Updates

News unavailable.